vs
Orthofix Medical Inc.（OFIX）与VARONIS SYSTEMS INC（VRNS）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是VARONIS SYSTEMS INC的1.3倍（$219.9M vs $173.1M），VARONIS SYSTEMS INC同比增速更快（26.9% vs 2.0%），VARONIS SYSTEMS INC自由现金流更多（$49.0M vs $16.8M），过去两年VARONIS SYSTEMS INC的营收复合增速更高（15.2% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Varonis Systems是总部位于美国佛罗里达州迈阿密的软件企业，在以色列赫兹利亚设有研发中心。其推出的数据安全平台可分析数据及数据活动，借此识别由访问权限、SaaS应用配置不当引发的数据暴露风险，并可触发自动化修复流程，助力企业保障数据安全。
OFIX vs VRNS — 直观对比
营收规模更大
OFIX
是对方的1.3倍
$173.1M
营收增速更快
VRNS
高出24.9%
2.0%
自由现金流更多
VRNS
多$32.2M
$16.8M
两年增速更快
VRNS
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $173.1M |
| 净利润 | $-2.2M | — |
| 毛利率 | 71.1% | 76.0% |
| 营业利润率 | 0.2% | -1.7% |
| 净利率 | -1.0% | — |
| 营收同比 | 2.0% | 26.9% |
| 净利润同比 | 92.4% | — |
| 每股收益（稀释后） | $-0.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXVRNS
| Q1 26 | — | $173.1M | ||
| Q4 25 | $219.9M | $173.4M | ||
| Q3 25 | $205.6M | $161.6M | ||
| Q2 25 | $203.1M | $152.2M | ||
| Q1 25 | $193.6M | $136.4M | ||
| Q4 24 | $215.7M | $158.5M | ||
| Q3 24 | $196.6M | $148.1M | ||
| Q2 24 | $198.6M | $130.3M |
净利润OFIXVRNS
| Q1 26 | — | — | ||
| Q4 25 | $-2.2M | $-27.8M | ||
| Q3 25 | $-22.8M | $-29.9M | ||
| Q2 25 | $-14.1M | $-35.8M | ||
| Q1 25 | $-53.1M | $-35.8M | ||
| Q4 24 | $-29.1M | $-13.0M | ||
| Q3 24 | $-27.4M | $-18.3M | ||
| Q2 24 | $-33.4M | $-23.9M |
毛利率OFIXVRNS
| Q1 26 | — | 76.0% | ||
| Q4 25 | 71.1% | 78.9% | ||
| Q3 25 | 72.2% | 78.2% | ||
| Q2 25 | 68.7% | 79.5% | ||
| Q1 25 | 62.8% | 78.7% | ||
| Q4 24 | 69.0% | 83.6% | ||
| Q3 24 | 68.7% | 83.8% | ||
| Q2 24 | 67.8% | 82.8% |
营业利润率OFIXVRNS
| Q1 26 | — | -1.7% | ||
| Q4 25 | 0.2% | -17.5% | ||
| Q3 25 | -8.3% | -22.2% | ||
| Q2 25 | -7.9% | -24.0% | ||
| Q1 25 | -25.2% | -32.1% | ||
| Q4 24 | -5.3% | -11.1% | ||
| Q3 24 | -9.6% | -16.0% | ||
| Q2 24 | -12.5% | -22.1% |
净利率OFIXVRNS
| Q1 26 | — | — | ||
| Q4 25 | -1.0% | -16.0% | ||
| Q3 25 | -11.1% | -18.5% | ||
| Q2 25 | -6.9% | -23.5% | ||
| Q1 25 | -27.4% | -26.2% | ||
| Q4 24 | -13.5% | -8.2% | ||
| Q3 24 | -13.9% | -12.4% | ||
| Q2 24 | -16.8% | -18.4% |
每股收益（稀释后）OFIXVRNS
| Q1 26 | — | — | ||
| Q4 25 | $-0.05 | $-0.23 | ||
| Q3 25 | $-0.57 | $-0.26 | ||
| Q2 25 | $-0.36 | $-0.32 | ||
| Q1 25 | $-1.35 | $-0.32 | ||
| Q4 24 | $-0.76 | $-0.12 | ||
| Q3 24 | $-0.71 | $-0.16 | ||
| Q2 24 | $-0.88 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $179.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $453.5M |
| 总资产 | $850.6M | $1.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXVRNS
| Q1 26 | — | $179.3M | ||
| Q4 25 | $82.0M | $883.7M | ||
| Q3 25 | $62.9M | $671.3M | ||
| Q2 25 | $65.6M | $770.9M | ||
| Q1 25 | $58.0M | $567.6M | ||
| Q4 24 | $83.2M | $529.0M | ||
| Q3 24 | $30.1M | $844.8M | ||
| Q2 24 | $26.4M | $582.5M |
总债务OFIXVRNS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — |
股东权益OFIXVRNS
| Q1 26 | — | $453.5M | ||
| Q4 25 | $450.0M | $598.7M | ||
| Q3 25 | $442.5M | $604.8M | ||
| Q2 25 | $458.3M | $341.5M | ||
| Q1 25 | $458.3M | $367.7M | ||
| Q4 24 | $503.1M | $455.7M | ||
| Q3 24 | $525.9M | $428.6M | ||
| Q2 24 | $546.0M | $458.6M |
总资产OFIXVRNS
| Q1 26 | — | $1.6B | ||
| Q4 25 | $850.6M | $1.8B | ||
| Q3 25 | $832.6M | $1.7B | ||
| Q2 25 | $837.2M | $1.6B | ||
| Q1 25 | $823.1M | $1.6B | ||
| Q4 24 | $893.3M | $1.7B | ||
| Q3 24 | $867.9M | $1.5B | ||
| Q2 24 | $882.0M | $1.1B |
负债/权益比OFIXVRNS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $55.0M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $49.0M |
| 自由现金流率自由现金流/营收 | 7.6% | 28.3% |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $118.2M |
8季度趋势，按日历期对齐
经营现金流OFIXVRNS
| Q1 26 | — | $55.0M | ||
| Q4 25 | $27.7M | $24.7M | ||
| Q3 25 | $12.4M | $33.4M | ||
| Q2 25 | $11.6M | $21.3M | ||
| Q1 25 | $-18.4M | $68.0M | ||
| Q4 24 | $23.7M | $24.3M | ||
| Q3 24 | $11.7M | $22.5M | ||
| Q2 24 | $9.0M | $11.7M |
自由现金流OFIXVRNS
| Q1 26 | — | $49.0M | ||
| Q4 25 | $16.8M | $20.7M | ||
| Q3 25 | $2.5M | $30.4M | ||
| Q2 25 | $4.5M | $18.0M | ||
| Q1 25 | $-25.1M | $65.7M | ||
| Q4 24 | $15.2M | $19.9M | ||
| Q3 24 | $6.3M | $21.3M | ||
| Q2 24 | $-360.0K | $10.9M |
自由现金流率OFIXVRNS
| Q1 26 | — | 28.3% | ||
| Q4 25 | 7.6% | 12.0% | ||
| Q3 25 | 1.2% | 18.8% | ||
| Q2 25 | 2.2% | 11.8% | ||
| Q1 25 | -13.0% | 48.1% | ||
| Q4 24 | 7.0% | 12.6% | ||
| Q3 24 | 3.2% | 14.4% | ||
| Q2 24 | -0.2% | 8.4% |
资本支出强度OFIXVRNS
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 2.3% | ||
| Q3 25 | 4.8% | 1.8% | ||
| Q2 25 | 3.5% | 2.2% | ||
| Q1 25 | 3.5% | 1.7% | ||
| Q4 24 | 4.0% | 2.7% | ||
| Q3 24 | 2.7% | 0.8% | ||
| Q2 24 | 4.7% | 0.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
VRNS
| SaaS | $161.1M | 93% |
| Term license subscriptions | $6.9M | 4% |
| Maintenance and services | $5.2M | 3% |
